NICE says no to daclizumab (Zinbryta)

[MSUK]

In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states:

Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults... Read more - http://www.ms-uk.org/nice-says-no-dacli ... yta-051016

[HarryZ]

In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states:

Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults... Read more - http://www.ms-uk.org/nice-says-no-dacli ... yta-051016

Daclizumab is an experimental drug treatment being developed for relapsing remitting MS. It is taken as an injection under the skin, once a month. In clinical trials, daclizumab reduced relapse rates by approximately 50% compared to placebo and by 45% compared to beta interferon. The drug was licensed in Europe in July 2016.

Now what does this info say about beta inferferon?!!! Only a 5 % better result than by taking nothing?